{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:06:09Z","timestamp":1776081969818,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008196","name":"M\u00e9decins Sans Fronti\u00e8res","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 MDR-TB patients (19.4% HCV), 30 were treated concomitantly (23.3% human immunodeficiency virus-positive). Overall, 76.7% achieved HCV treatment success (95.8% among tested). One patient (3.3%) experienced a serious adverse event.<\/jats:p>","DOI":"10.1093\/ofid\/ofaa653","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T16:26:20Z","timestamp":1609777580000},"source":"Crossref","is-referenced-by-count":10,"title":["Concomitant Treatment of Chronic Hepatitis C With Direct-Acting Antivirals and Multidrug-Resistant Tuberculosis Is Effective and Safe"],"prefix":"10.1093","volume":"8","author":[{"given":"Nara","family":"Melikyan","sequence":"first","affiliation":[{"name":"Epicentre, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Huerga","sequence":"additional","affiliation":[{"name":"Epicentre, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakob","family":"Atshemyan","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Yerevan, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ohanna","family":"Kirakosyan","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Yerevan, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narina","family":"Sargsyants","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Yerevan, Armenia"},{"name":"Ministry of Health, Yerevan, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsovinar","family":"Aydinyan","sequence":"additional","affiliation":[{"name":"Ministry of Health, Yerevan, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Saribekyan","sequence":"additional","affiliation":[{"name":"Ministry of Health, Yerevan, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naira","family":"Khachatryan","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Yerevan, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabella","family":"Oganezova","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Yerevan, Armenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Falcao","sequence":"additional","affiliation":[{"name":"Epicentre, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suna","family":"Balkan","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Hewison","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"2021022016382945900_CIT0001","author":"World Health Organization"},{"key":"2021022016382945900_CIT0002","author":"World Health Organization"},{"key":"2021022016382945900_CIT0003","doi-asserted-by":"crossref","first-page":"800","DOI":"10.5588\/ijtld.15.0668","article-title":"Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis","volume":"20","author":"Lee","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021022016382945900_CIT0004","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2021022016382945900_CIT0005","doi-asserted-by":"crossref","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"},{"key":"2021022016382945900_CIT0006","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s12072-018-9856-z","article-title":"Ledipasvir\/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study","volume":"12","author":"Wei","year":"2018","journal-title":"Hepatol Int"},{"key":"2021022016382945900_CIT0007","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hep.28625","article-title":"Real-world effectiveness of ledipasvir\/sofosbuvir in 4365 treatment-naive, genotype 1 hepatitis C-infected patients","volume":"64","author":"Backus","year":"2016","journal-title":"Hepatology"},{"key":"2021022016382945900_CIT0008","first-page":"137","article-title":"Effectiveness and safety of daclatasvir\/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice","volume":"32","author":"Margusino-Frami\u00f1\u00e1n","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"2021022016382945900_CIT0009","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijantimicag.2017.01.016","article-title":"Effectiveness of ledipasvir\/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach","volume":"49","author":"Johnson","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2021022016382945900_CIT0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"2021022016382945900_CIT0011","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"2021022016382945900_CIT0012","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1186\/s12879-019-4494-1","article-title":"Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis","volume":"19","author":"Musso","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2021022016382945900_CIT0013","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41124-017-0026-z","article-title":"Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries","volume":"2","author":"Maistat","year":"2017","journal-title":"Hepatol Med Policy"},{"key":"2021022016382945900_CIT0014","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/cid\/ciz628","article-title":"SD1000: high sustained viral response rate in 1361 patients with hepatitis C genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tablet of generic sofosbuvir and daclatasvir: a multicenter, phase III clinical trial","volume":"70","author":"Merat","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021022016382945900_CIT0015","first-page":"e01215","article-title":"A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment","volume-title":"Antimicrob Agents Chemother","author":"Kempker","year":"2019"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa653\/35385177\/ofaa653.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/2\/ofaa653\/36328660\/ofaa653.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/2\/ofaa653\/36328660\/ofaa653.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T05:22:55Z","timestamp":1613884975000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa653\/6062163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa653","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2021,1,4]]},"article-number":"ofaa653"}}